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Abstract
Background: Alemtuzumab, an anti-CD52 monoclonal antibody, was administered to patients with RA between
1991 and 1994. We have followed a cohort of recipients since that time and previously reported significant delays
in immune reconstitution. Here we report >20 years of follow-up data from this unique cohort.
Method: Surviving alemtuzumab recipients were age, sex and disease duration matched with RA controls. Updated
mortality and morbidity data were collected for alemtuzumab recipients. For both groups antigenic responses were
assessed following influenza, Pneumovax II and combined diphtheria/tetanus/poliovirus vaccines. Circulating
cytokines and lymphocyte subsets were also quantified.
Results: Of 16 surviving alemtuzumab recipients, 13 were recruited: 9 recipients underwent a full clinical
assessment and 4 had case notes review only. Since our last review 10 patients had died from causes of death
consistent with long-standing RA, and no suggestion of compromised immune function. Compared with controls
the alemtuzumab cohort had significantly reduced CD4+ and CD8+ central memory T-cells, CD5+ B cells, naïve B
cells and CD19+CD24hiCD38hi transitional (putative regulatory) B cells. Nonetheless vaccine responses were
comparable between groups. There were significantly higher serum IL-15 and IFN-γ levels in the alemtuzumab
cohort. IL-15 levels were inversely associated with CD4+ total memory and central memory T cells.
Conclusion: After 20 years the immune system of alemtuzumab recipients continues to show differences from
disease controls. Nonetheless mortality and morbidity data, alongside vaccination responses, do not suggest clinical
immune compromise. As lymphodepleting therapies, including alemtuzumab, continue to be administered this
work is important with regard to long-term immune monitoring and stages of immune recovery.
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Background
Targeted immunomodulatory therapies have revolutionised
the treatment of autoimmune diseases, particularly rheuma-
toid arthritis (RA). Alemtuzumab (CAMPATH-1H) was the
first humanised therapeutic monoclonal antibody and acts
by depleting cells expressing CD52, which includes T and B
lymphocytes, monocytes, and natural killer (NK) cells.
Alemtuzumab was initially used with some success to treat
several cohorts of refractory RA patients in the early 1990s;
however, given the resultant profound lymphopenia, particu-
larly in the CD4+ compartment, trials in RA were curtailed
[1]. We previously reported delayed reconstitution of the
immune system following the treatment of RA with
alemtuzumab, particularly of T cells and CD5+ B cells, but
with no apparent adverse effects on 12-year morbidity or
mortality or on the response to antigenic challenges [2, 3].
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Iatrogenic lymphopenia is becoming increasingly rele-
vant as depleting therapies are more widely used in the
treatment of cancer, transplantation and also auto-
immunity. For example alemtuzumab is now licenced
for use in relapsing-remitting multiple sclerosis [4].
Furthermore there are suggestions that rituximab, an in-
creasingly commonly administered B cell depleting
therapy for the treatment of RA, also depletes CD4+ T
cells [5]. Thus, understanding the dynamics of immune
reconstitution and the long-term outcome of depleting
therapies is becoming increasingly important in wider
clinical practice. We report here the 20-year follow up of
our original cohort of patients with RA treated with
alemtuzumab.
Methods
Patients and controls
Patients who were treated with alemtuzumab (CAM-
PATH-1H) for RA between 1991 and 1994 were
identified from the study database. Cumulative alem-
tuzumab doses were documented for each individual;
of note, these doses were comparatively lower than
those seen with other more widely used biological
therapies. Mortality data for this cohort were col-
lected from 9 March 2006 (end date of our previous
study) until 1 January 2015 from the National Health
Service Central Registry. Morbidity information was
collected on all living and consenting patients by ei-
ther interview or review of clinical case notes. Special
attention was given to episodes of severe infection,
cancers and autoimmunity. Age and sex matched pa-
tients with RA of similar disease duration, who had
not received alemtuzumab, were identified locally in
Cambridge, UK. Research was performed in compli-
ance with the Declaration of Helsinki and the Inter-
national Conference on Harmonisation Good Clinical
Practice. Ethical approval for the study was provided
by Scotland A Research Ethics Committee (REC 10/
MRE00/68).
Clinical parameters
Clinical and serological parameters were obtained from
all patients attending interview. Markers of disease activ-
ity included erythrocyte sedimentation rate (ESR), C-
reactive protein (CRP), tender joint count (TJC), swollen
joint count (SJC), patient-reported visual analogue scale
(VAS), disease activity score in 28 joints (DAS-28)-ESR
and patient health assessment questionnaire (HAQ). Anti-
cyclic citrullinated peptide (anti-CCP) antibody and rheuma-
toid factor (RF) IgM titres and serum immunoglobulins
(IgG, IgA, IgM), serum electrophoresis and lymphocyte
count were analysed in the clinical laboratories of Adden-
brooke’s Hospital, Cambridge, according to routine clinical
practice and national standards.
Vaccine responses
Subjects were offered vaccination with: 0.5 ml influenza
vaccine (Pfizer Ltd, Sandwich, UK), a split, inactivated
influenza vaccine containing antigens equivalent to A/
California/7/2009 (H1N1) pdm09-derived strain (NYMC
X-181), A/Victoria/361/2011 (H3N2)-derived strain (IVR-
165) and B/Wisconsin/1/2010–like strain (NYMC BX-39)
derived from B/Hubei- B/ Wujiagang/158/2009; 0.5 ml
Pneumovax II (Sanofi Pasteur MSD Ltd, Maidenhead,
UK), a vaccine containing 25 μg of each of the following
23 pneumococcal polysaccharide serotypes: 1, 2, 3, 4, 5,
6B, 7 F, 8, 9 N, 9 V, 10A, 11A, 12 F, 14, 15B, 17 F, 18C,
19 F, 19A, 20, 22 F, 23 F, 33 F; and 0.5 ml Revaxis (Sanofi
Pasteur MSD Ltd, Maidenhead, UK) containing 2 IU puri-
fied diphtheria toxoid, 20 IU purified tetanus toxoid and
inactivated poliomyelitis virus types 1-3.
Vaccine responses were assessed in serum obtained at
baseline and 4 weeks post vaccination. Analyses were per-
formed at the Respiratory Virus Unit, Health Protection
Agency, London UK (influenza), the Vaccine Evaluation
Unit, Public Health England, Manchester (pneumococcus,
diphtheria and tetanus) and Public Heath England, Enteric
Virus Unit, London (poliovirus). Satisfactory response to
pneumococcal vaccine was defined as a doubling (or
greater) in antibody concentrations to 6 or more of 12
pneumococcal serotypes (1, 3, 4, 5, 6B, 7 F, 9 V, 14, 19A,
19 F, 23 F and 18C). Tetanus and diphtheria seroprotection
was achieved when IgG titres were >1.0 IU/ml. These were
booster vaccines and some patients had residual seroprotec-
tion pre-administration. These patients were excluded from
subsequent seroconversion analysis, which was defined as
when vaccination achieved new seroprotection.
For poliovirus, neutralizing antibodies were quantified,
with seroprotection with titres ≥1:8 and seroconversion
following ≥4 fold increase in titres. For influenza, HAI
assays were performed, with seroprotection when titres
were >1:40 and seroconversion when post-vaccination
titre increased by ≥3 fold. The seroconversion factor was
the mean rise in geometric mean titres (GMT) post
vaccination (recommended ≥2) and seroconversion rate
was the percentage of vaccinees with an increase in
haemagglutination inhibition (HAI) titre ≥4 fold follow-
ing vaccination (recommended >30%). Some patients
had annual influenza vaccines prior to recruitment into
the study. These individuals were not vaccinated again
but anti-influenza titres were measured in baseline
serum. Any adverse effects were collected 4 weeks post
vaccination.
Serum cytokines
At the initial visit cytokines (IL-15, IL-7, IFN-γ, IL-10,
IL-12, IL-13, IL1-beta, IL-2, IL-4, IL-6, IL-8, TNF-alpha
and granulocyte macrophage colony stimulating factor
(GM-CSF)) were measured in serum by MSD technology
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(Meso Scale Discovery, MD, USA) as per established
protocol.
Immunophenotyping
Peripheral blood lymphocytes were immunophenotyped
by multicolour flow cytometry using the following
antibodies: anti-CD3 Pacific Blue, anti-CD56 FITC,
Anti-CD27 PE, anti-CD28 APC, anti-CD1d PE, anti-
CD19 APC, anti-CD27 V450, anti-CD38 PerCP-Cy5.5
(all from BD Biosciences, San Jose, CA, USA) and anti-
CD45RA PerCP-Cy5.5, anti-CD62L PE-Cy7, anti-CD5
PE-Cy7, anti-CD24 APC-eFluor 780 and anti-CD4 APC-
eFluor 780 (from eBioscience, Inc. San Diego, CA, USA).
Staining was performed on whole blood using BD FACS
Lysing Solution (BD Biosciences) as per the manufac-
turer’s instructions. A minimum of 250,000 events were
acquired for T cell panels and 500,000 events for B cell
panels to ensure adequate capture of rare populations.
Subsequent detailed analysis of lymphocyte sub-
populations was performed on the gated lymphocyte
population using FlowJo (Treestar, Inc., OR, USA). Ab-
solute counts for the different lymphocyte populations
were calculated per litre of blood, based on haematology
laboratory reported total lymphocyte count.
Statistical analysis
Statistical analysis was performed using the Mann-Whitney
U test, Wilcoxon signed rank test and linear regression
using Prism 4.0 (GraphPad Software, Inc., La Jolla, CA,
USA). P values <0.05 were considered significant.
Results
Demographics
Sixteen patients from the original alemtuzumab cohort
were alive at the time of recruitment. Nine agreed to be
interviewed and to provide a blood sample in conjunction
with vaccination. An additional four patients agreed to
their clinical notes being reviewed, two declined and one
could not be contacted. A further eight age and sex
matched patients with established RA of a similar disease
duration were recruited as controls. Cohort demographics,
current treatment and (where applicable) past alemtzu-
mab treatment dose are shown in Tables 1, 2 and 3.
Briefly, the median age of the entire alemtuzumab co-
hort was 68 (range 45–81) years, 69% were female, the
median disease duration was 31 years (range 23–43) and
the median alemtuzumab cumulative dose was 62 mg
(range 2–400 mg). Patients who underwent vaccination
and peripheral blood analysis had a median age of
65 years (range 45–81), 77% of them were female, the
median disease duration was 31 years (range 23–40), the
median DAS-28 was 3.44 (range 1.38–5.33) and the me-
dian alemtuzumab cumulative dose was 60 mg (range
18–400 mg). The median age in the controls was
61.5 years (range 52–79), 87.5% were female, the median
disease duration was 24.5 years (range 20–41) and the
median DAS-28 was 3.90 (range 2.03–5.75). There was
no significant difference in age, sex, disease duration,
SJC, TJC or DAS-28 between the cohorts that under-
went vaccination. The alemtuzumab cohort had a higher
HAQ score (median 2.25 compared with 1.69 in con-
trols), CRP (median 7 compared with <5 in controls)
and ESR (median 34 compared with 11.5 in controls).
Nine of the alemtuzumab cohort were taking conven-
tional synthetic disease-modifying anti-rheumatic drugs
(csDMARDs) only, three were receiving biological
DMARD (bDMARD) monotherapy and one was receiv-
ing concurrent bDMARDs and csDMARDs. One of
these patients had recently received rituximab prior to
being switched to their current therapy (abatacept) and
was therefore excluded from B cell analysis. No further
patients in either the control or alemtuzumab cohorts
had previously received rituximab. In the control cohort
four patients were taking csDMARDs only, three were
receiving both csDMARDs and bDMARDs and one was
receiving bDMARD monotherapy.
There was no significant difference in immunoglobulin
titres (IgG, IgA and IgM) between the alemtuzumab and
established RA control cohort. RF titres were performed
in all patients, and anti-CCP antibody titres were ob-
tained in eight patients taking alemtuzumab and five
controls. The median RF titre inr the alemtuzumab co-
hort was 0 IU, (range 0–67 IU) and in the controls the
median was 39 IU (range 0–275) (p = 0.06). The median
anti-CCP value in alemtuzumab patients was 0.55 U/ml
(range 0–340) and in controls it was 215 U/ml (range
1.2–340) (p = 0.039).
Mortality and morbidity
Ten patients in the alemtuzumab cohort had died since
our previous review. Causes of mortality, as per death
certificate documentation, are outlined in Table 4. Three
cases of malignancy were noted (brain tumour, lung
adenocarcinoma and carcinomatosis with unknown pri-
mary). Infection was listed as cause of/contributor to
death in four patients (three patients with respiratory
(one with concurrent cellulitis) and one with urinary ori-
gin). Cardiovascular disease was a contributor in two pa-
tients (congestive cardiac failure and vascular dementia)
and was implicated in one other (respiratory failure and
congestive cardiac failure). The remaining causes/con-
tributors to death were dementia, pulmonary fibrosis
and chronic obstructive pulmonary disease.
Compilation of the primary causes of death from the
entire cohort from 1994 to 2015 (Table 5) showed over-
all 37 of the original 53 patients who received alemtuzu-
mab had died. The predominant causes of death were
cardiovascular/atherosclerotic (n = 12), infection (n = 11),
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and malignancy (n = 8). Other causes were non-
malignant gastrointestinal tract perforation (n = 2), pul-
monary fibrosis (n = 1), dementia (n = 1), upper gastro-
intestinal bleed (n = 1) and primary sclerosing
cholangitis (n = 1).
Morbidity in the 13 alemtuzumab patients (interview
and case note review) focused on new medical diagno-
ses, particularly malignancy, episodes of severe infection
and autoimmunity. Two patients had a new diagnosis of
malignancy, both of which were skin cancers with a
background of Bowen’s disease. Two had new auto-
immune conditions - hyperthyroidism and coeliac dis-
ease. The remaining new diagnoses were osteoporosis,
osteoarthritis, vitamin D deficiency, cardiac arrhythmia
and ischaemic heart disease. There were no reports of
severe infection.
Alemtuzumab patients have persistent circulating
lymphocyte abnormalities
We previously reported that at a mean follow up of 12 years
after treatment, our alemtuzumab cohort remained pro-
foundly lymphopenic [1, 3]. While our current analysis
(Table 6) suggests that compared with age and sex
matched disease controls, overall lymphopenia had now
resolved (p = 0.7001), specific differences remained. CD4+
and CD8+ central memory subsets remained low (p =
0.0360 and p = 0.0274 respectively) and we noted B cell
lymphopenia (p = 0.0041), even after excluding a patient
who had recently received rituximab. This predominantly
reflects reduced naïve B cells (p = 0.0041) but a previously
highlighted deficiency of CD5+CD19 B cells (p = 0.0175)
persists. There is also a significant reduction in CD19
+CD24hiCD38hi transitional B cells (Fig. 1a). However
other previously noted abnormalities had normalised; in
particular naïve and effector memory T cell populations
and NK cells were not different to controls.
Seropositive patients with RA have persistently reduced
RF titres following alemtuzumab therapy
We reviewed RF titres as documented in the medical
notes at the time of alemtuzumab administration. Of
Table 2 Alemtuzumab patient and RA patient control pooled
demographic and serological data. P value: alemtuzumab
patients vs established controls. Values in italics are significant
(p < 0.05)
Characteristic Alemtuzumab Treated
patients
RA Control
patients
P value
Age (Years)
median, range
65
[45–81]
61.5
[52–79]
0.773
Sex
male/female, %
77%
F
87.5%
F
0.600
Disease Duration (Years)
median, range
31
[23–40]
24.5
[20–41]
0.200
Alemtuzumab total dose
(mg)
median, range
60
[18–400]
- -
DAS-28
median, range
3.44
[1.38-5.33]
3.9
[2.03-5.75]
0.743
CRP (mg/L)
median, range
7
[<5-134]
<5
[all <5]
0.001
ESR (mm/hr)
median, range
34
[4–104]
11.5
[2–38]
0.03
HAQ
median, range
2.25
[2–3]
1.69
[0.25-2.13]
0.025
VAS
median, range
25
[2–56]
23
[4–75]
0.847
SJC (n)
median, range
0
[0–2]
1
[0–7]
0.414
TJC (n)
median, range
1
[0–6]
3
[0–20]
0.154
IgG (g/L)
median, range
9.5
[6.2 – 16.6]
9.95
[4.4-16.3]
0.916
IgA (g/L)
median, range
2.6
[1.1 – 4.2]
1.9
[40.4 -3.9]
0.431
IgM (g/L)
median, range
0.85
[0.006 - 3.2]
0.85
[0.3 -2.5]
0.874
RF (IU)
median, range
0
[0–67]
39
[0–275]
0.060
CCP (U/ml)
median, range
0.55
[0–340]
215
[1.2-340]
0.039
Table 3 Alemtuzumab patient demographical data for whom
only morbidity and current conventional synthetic or biological
DMARD therapy data was obtained
Age
(Years)
Sex Disease
Duration
(Years)
Alemtuzumab
total dose (mg)
DMARD/
Biological
therapy
CAM14 68 F 35 62 MTX
CAM15 69 M 23 400 HCQ
CAM16 75 F 26 260 MTX, HCQ
CAM24 63 M 43 2 ADA
MTX - methotrexate; HCQ – hydroxychloroquine; ADA – adalimumab
Table 4 Mortality from 9 March 2006 to 1 January 2015 in
patients with rheumatoid arthritis who received alemtuzumab
between 1991 and 1994
Age at death, years Cause of death
78 Carcinomatosis, unknown primary, rheumatoid
arthritis
79 Bronchopneumonia, rheumatoid arthritis, cellulitis
58 Respiratory failure, pulmonary oedema
89 Bronchopneumonia, congestive cardiac failure
77 Pneumonia, vascular dementia
71 Brain tumour
76 Sepsis, urinary tract infection, chronic obstructive
pulmonary disease, rheumatoid arthritis
69 Adenocarcinoma of the lung
79 Pulmonary fibrosis
75 Dementia, rheumatoid arthritis
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our current alemtuzumab cohort only two patients
had positive RF at the time of alemtuzumab therapy,
but these values were now reduced compared to base-
line values 20 years earlier (432→ 20 IU/ml and
57→ 25 IU/ml). We therefore looked at data from
eight additional (deceased) RF-positive patients who
had received alemtuzumab, and compared their base-
line RF titres with titres published at their last follow
up [2]. Whilst not being statistically significant (p =
0.084), there was a reduction in RF titres 12 years
after alemtuzumab treatment (Fig. 1b).
Vaccine responses in patients receiving alemtuzumab and
in controls
All patients who attended interview were offered vaccin-
ation, dependent on their vaccination status at the time.
Four patients on alemtuzumab and three controls received
influenza vaccine, the remainder having already received
seasonal influenza vaccine prior to recruitment. For these
latter patients we assessed the seroprotection rate only.
Seven patients on alemtuzumab and six controls received
pneumococcus vaccination, the others having been vacci-
nated within the last 5 years (n = 2) or having declined
vaccination (n = 2). Six patients on alemtuzumab and four
control patients received the combined diphtheria, tetanus
and polio vaccine. There were no significant adverse
events following any vaccination.
Due to the small numbers in both groups, robust
statistical comparison was not possible. Nonetheless we
observed similar levels of seroprotection following polio-
virus (P1-P3), tetanus and diphtheria vaccination,
whereas for pneumococcal antigen, seroprotection
appeared higher in the alemtuzumab cohort. Serocon-
version was comparable for tetanus and diphtheria, al-
though potentially lower in alemtuzumab recipients for
polio. For influenza seroprotection, the rates in the
4 weeks post vaccine were similar in both cohorts, al-
though the seroconversion rate was uniformly poor.
When including those who had influenza vaccines ad-
ministered outside this study we saw a lower seroprotec-
tion rate in the alemtuzumab patients; however, the
timing of the prior vaccination was unknown, making
meaningful comparison difficult (Table 7).
Cytokines
There were significantly higher serum IFN-γ (p < 0.0001)
and IL-15 (p = 0.019) levels detected in the alemtuzumab
cohort compared with controls (Fig. 2a). There was a
significant inverse association between serum IL-15 and
CD4+ total memory and central memory T cells (p =
0.034 and p = 0.037), see Fig. 2b and c. A similar trend
for CD8+ total memory and central memory T cells was
also seen albeit not significant (p > 0.05). There were no
significant associations detected in the effector memory
compartments.
Discussion
Lymphocyte depleting therapies continue to be used in
autoimmunity and transplantation [4, 6]; indeed, in a
current phase-I clinical trial investigating the therapeutic
potential of stem cell transplantation for RA, alemtuzu-
mab is being administered as part of the immunosup-
pressive regimen [7]. Furthermore, novel targets of
immunomodulation such as the JAK inhibitor tofacitinib
can also reduce CD4+ and CD8+ T cells and natural
killer (NK) cells in vivo [8]. Thus, immune reconstitu-
tion is of relevance to a growing range of therapies. Here
we present 20-year follow-up data on a unique cohort of
patients with RA treated with the lymphodepleting agent
alemtuzumab.
Causes of death in this most recent follow up are in keep-
ing with our previous observations, with four cases of infec-
tion (three pulmonary), three tumours, and single cases of
respiratory failure (secondary to pulmonary oedema),
dementia and pulmonary fibrosis (Tables 4 and 5). We pre-
viously demonstrated that overall mortality did not differ be-
tween alemtuzumab recipients and a comparable (external)
control population. However, the original control cohort is
no longer under follow up, and cause-specific mortality
comparisons were not performed due to the small size of
the alemtuzumab cohort. Overall, however, the major causes
of death (cardiovascular, pulmonary infection and malig-
nancy, particularly pulmonary) is in keeping with other
established RA cohorts [9].
We documented two new cases of autoimmunity
(hyperthyroidism and coeliac disease) but secondary
Table 5 Mortality from 1994 to 1 January 2015 in patients with
rheumatoid arthritis who received alemtuzumab between 1991
and 1994
Number
of patients
Primary cause of death
All deaths 37
Cardiovascular
and atherosclerotic
disease
12 Ischaemic heart disease (n = 8),
respiratory compromise secondary
to heart failure (n = 1), multi infarct
dementia (n = 1), bowel infarction
secondary to atrial fibrillation (n = 1),
superior mesenteric artery
infarction (n = 1)
Infection 11 Respiratory (n = 10), renal tract (n = 1)
Malignancy 8 Lung primary (n = 3), non-Hodgkin’s
lymphoma (n = 1), breast primary
(n = 1), brain tumour (n = 1), stomach
leiomyosarcoma (n = 1), unknown
primary (n = 1)
Other 6 Non-malignant gastrointestinal tract
perforation (n = 2), pulmonary fibrosis
(n = 1), dementia (n = 1), upper
gastrointestinal bleed (n = 1),
primary sclerosing cholangitis (n = 1)
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autoimmunity has been much less common in RA recipi-
ents of alemtuzumab than in multiple sclerosis (MS) co-
horts. In the latter, autoimmunity affected approximately
one third of alemtuzumab recipients and peaked after
2 years. It is mainly, but not exclusively, thyroid in nature
and has been linked to tolerance breakdown during the
homeostatic proliferation component of immune
reconstitution [10]. Additionally a recent retrospective
study of alemtuzumab use in Bechet’s disease demon-
strated that approximately two thirds of patients achieved
lymphocyte recovery by a median of 9 months, but 25% of
patients developed secondary autoimmune thyroid disease
[11]. Whilst patients affected by these diseases clearly in-
herit distinct genetic backgrounds [12], our data
Fig. 1 a Absolute counts (×109/L) of different B cell populations; A alemtuzumab cohort, C controls. In the alemtuzumab cohort there was significant
reduction in the frequency of CD19+ B cells (p= 0.0041), CD19+CD5+ B cells (p= 0.0175), naïve B cells (CD19+CD27-) (p=0.0041), and CD19+CD24hiCD38hi B
cells (p= 0.003). b Rheumatoid factor (RF) titres (IU) in patients with rheumatoid arthritis (n= 10) pre and post treatment with alemtuzumab. The post
treatment titres are either 12 years (n= 8) or 20 years (n= 2) after alemtuzumab administration. We show a clear trend in fall in RF titres in 9/10 patients but
this was not statistically significant (p= 0.084). *p <0.05, **p< 0.01
Table 7 Responses to vaccination in alemtuzumab (ALEM) and control cohorts (CON)against diphtheria, tetanus, polio virus (P1-P3),
pneumococcal antigen and influenza
Diphtheria toxoid Tetanus Toxoid Poliovirus
P1 P2 P3 Pneumococcus antigen
Alem
(n = 6)
Controls
(n = 4)
Alem
(n = 6)
Con
(n = 4)
Alem
(n = 6)
Con
(n = 4)
Alem
(n = 6)
Con
(n = 4)
Alem
(n = 6)
Con
(n = 4)
Alem
(n = 7)
Con
(n = 6)
Seroprotection rate, % 66 25 100 100 100 100 83.3 100 83.3 100 _
Seroconversion rate, % 33 25 66.7 50 50 100 16.6 100 83.3 100
% Satisfactory response _ 66 0
Influenza vaccine titres A/Cal/7/09 A/Texas/50/12 B/Mass/02/12
Alem Con Alem Con Alem Con
Patients vaccinated
at interview
Alem n = 4
Controls, n = 3
GMT pre-vaccination 2.92 4.82 3.27 5.96 1.88 2.74
GMT post-vaccination 3.42 5.16 3.53 6.17 1.98 2.61
Seroconversion factor 1.16 1.07 1.08 1.03 1.05 0.85
Seroprotection rate, % 50 66.7 50 100 25 33.3
Seroconversion rate, % 25 0 0 0 0 0
Alem* n = 9
Controls* n = 8
Seroprotection rate, % 22 87.5 56 87.5 11 37.5
Tetanus and diphtheria seroprotection was achieved when respective IgG titres were >1.0 IU/ml and seroconversion was defined as new seroprotection. For polio
subtypes (P1-P3) seroprotection was a neutralizing antibody titre of ≥1:8 and seroconversion a ≥ fourfold increase in titres. Satisfactory response for pneumococcal
antigen was defined as a twofold or more increase from vaccination baseline in antibody concentrations in six or more of 12 pneumococcal serotypes (1, 3, 4, 5,
6B, 7 F, 9 V, 14, 19A, 19 F, 23 F and 18C). For influenza haemagglutination inhibition (HAI) titres >1:40 were defined as seroprotective and seroconversion was
defined as rises from negative titres to values of =/>1:40 (or fourfold titre increase if values were above baseline). Seroconversion factor was defined as the fold
increase in geometric mean HAI titres (GMT) post-vaccination (recommended ≥2) and seroconversion rate the percentage of vaccines with an increase in HAI
titre ≥ fourfold following vaccination (recommended >30%). Seroprotection rate (for all) was defined as percentage of group achieving seroprotection. *Including
patients who had influenza vaccine out with this study period
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demonstrate that patients with RA reconstitute more
slowly than their counterparts with MS or indeed Bechet’s,
which may reduce the incidence of secondary
autoimmunity.
Total lymphocyte counts in our alemtuzumab cohort
were now comparable with age, sex and disease duration-
matched RA controls but significant reductions in some
lymphocyte subsets remained. These persistently deranged
lymphocyte subsets are remarkable as alemtuzumab does
not target haemopoietic precursors and its half-life, when
used in the context of autoimmunity, is up to 5–6 days,
depending on the dosing regimen [13, 14]. There is a re-
duction in CD19+ B cells, comprising a persistent reduc-
tion in CD5+ B cells, and a newly identified reduction in
naïve B cells. CD5+ B cells have previously been reported
to be elevated in autoimmune conditions and involved in
autoantibody production, including RF [15–17]. Interest-
ingly we also noted a fall in RF titres following alemtuzu-
mab therapy in concert with the reduction in CD5+ B
cells. A potential caveat of this observation relates to the
technical differences in RF measurement over the inter-
vening years, thus, confounding these findings. Nonethe-
less, in the 1970s the World Health Organisation
proposed the use of international RF measurement units
[18], which markedly reduced inter-lab variability. Whilst
not measured at baseline, anti-CCP titres were much
lower in the alemtuzumab cohort than in matched
controls (Tables 1 and 2). More recently CD5+ B cells have
been reported to have a regulatory function [19–21], so
we also examined the frequency of CD19+CD24hiCD38hi
transitional B cells, which have putative regulatory func-
tion and are known to be reduced in RA [21, 22]. This
subset was further reduced in the alemtuzumab cohort
compared with the control cohort.
Despite reduced B cell numbers, and small numbers of
patients receiving vaccines, the vaccine responses ap-
peared comparable in the alemtuzumab and control co-
horts. Overall responses were generally poorer than
previously published in RA but both cohorts had sub-
stantially longer disease duration than those included in
previously published work [23]. None of the vaccines ad-
ministered were true neo-antigens but we concluded
that immune memory appears largely maintained in the
long term following alemtuzumab treatment.
A further unexpected finding was elevated levels of
circulating IL-15 and IFN-γ in our alemtuzumab cohort.
IL-15 closely resembles IL-2 in tertiary structure and is
important for T cell homeostasis. Central memory CD4+
and CD8+ T cells remained significantly reduced in the
current analysis and we observed a significant inverse
association between IL-15 and central memory CD4+ T
cells and a similar trend in central memory CD8+ T cells.
IL-15 enhances the function and inhibits apoptosis of
human CD4+ and CD8+ effector memory cells, which is
in keeping with our observed normal effector memory
CD8+ and CD4+ cell frequency [24]. In addition effector
memory CD4+ T cells are relatively resistant to alemtu-
zumab, which may have contributed to these observa-
tions [25, 26]. IL-15 also has potent effects on NK cells,
which proliferate and secrete IFN-γ [27, 28]. We have
previously emphasised the lack of serious and opportun-
istic infections in lymphopenic alemtuzumab recipients,
which could be underpinned by such homeostatic
mechanisms.
Conclusions
In conclusion, 20–25 years after initial administration of
alemtuzumab, causes of death remained consistent with
Fig. 2 a Circulating levels of serum IFN-γ and IL-15 (pg/ml) in the alemtuzumab cohort and controls. We show a significant increase in IFN-γ
(p < 0.0001) and IL-15 (p = 0.0188) in the alemtuzumab cohort. b, c CD4+ total memory and central memory T cells (cell number × 109/L) demonstrated
significant inverse associations with serum IL-15 (pg/ml) (p = 0.034, r2 = 0.286 and p = 0.037, r2 = 0.274 respectively). Results were considered significant
when the p value was <0.05. *p < 0.05, ***p < 0.0001
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those associated with long-standing RA. We continued
to see significant perturbations in lymphocyte subsets,
noting for the first time a reduction in naïve B cells and
CD19+CD24hiCD38hi potential Bregs, and a persistent
reduction in CD5+ B cells. Nonetheless, limited data sug-
gest that vaccine responses reflecting immune memory
are maintained. We also documented, for the first time, el-
evated circulating IL-15 and IFN-γ levels. Our data are re-
assuring and provide a unique insight into the long-term
consequences of potent lymphodepleting therapy in pa-
tients with RA. Whilst alemtuzumab is no longer used in
this setting, our findings are relevant to its use in other
settings and to other current and future targeted therap-
ies, and emphasise the importance of long-term follow up.
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α: tumour necrosis factor α; TOC: tocilizumab; VAS: visual analogue scale
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